Multicenter, Open-label Study to Assess Whether Treatment With Myfortic®(EC-MPS) Allows Higher Dose Optimization Versus Cellcept® (MMF) Leading to a Dose Reduction of Tacrolimus (Maximiza)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01056822
First received: January 25, 2010
Last updated: February 12, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)